KWKevin White

Kevin White

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kevin White has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Congenital Adnexal Carcinoma with Cribriform Pattern in a Pediatric Patient

    by Erika Koh, Oluwadamilare Ajayi, Danielle McClanahan, Louise van der Weyden, Jamie Billington, Josephine Iiott, David J. Adams, Timothy McCalmont, Kevin White

    Primary cutaneous adnexal carcinomas are exceedingly rare in pediatric patients. A 12-year-old girl presented to the dermatology clinic with a congenital subcutaneous nodule on the left buttock. The patient underwent wide local excision, and histopathologic findings demonstrated large nodular aggregates of atypical basaloid cells with a sieve-like pattern. Immunohistochemical stains were positive for p63, AE1/AE3, β-catenin, and EMA. CK7, CK20, CD117, SOX-10, and Ber-Ep4 were negative. To the best of our knowledge upon review of the literature, we describe a new entity of an adnexal carcinoma with a cribriform pattern in a pediatric patient. Although there was no clinical evidence of recurrence at follow-up, the biologic potential of this tumor is unknown.

  • Hypopigmented Junctional BAP1‐Inactivated Melanocytoma: A Paradigm Shift

    by Ali Gunesch, Iwei Yeh, Timothy McCalmont, Elizabeth Berry, Gretchen Vanderbeek, Kevin P. White

    Since their original description by Wiesner et al., the spectrum of clinical, histopathologic, and molecular findings of BAP1 (BRCA1‐associated protein 1)‐inactivated melanocytomas has been more fully characterized. Herein, we report an exceptional presentation of multiple junctional melanocytic BAP1‐inactivated melanocytomas with a clinically hypopigmented appearance in a patient. Targeted DNA sequencing demonstrated the same BAP1 frameshift mutation (BAP1 p.R59f) in three different lesions. One of the specimens also displayed two truncating mutations in NF1 (NF1 p.Q129* and NF1 p.Q1801*) at 8%–9% mutant allele frequency. To our knowledge, BIM confined entirely to the epidermis, and multiple BIMs presenting in hypopigmented fashion have not been widely reported previously.

  • Pediatric Dermatology, Pruritic Annular Vesiculobullous Plaques in a 10‐Year‐Old Female

    by Milie M. Fang, Carter Haag, Lynne H. Morrison, Kevin P. White, Tracy Funk


  • Granuloma annulare following initiation of interleukin‐17a antagonist

    by A. R. Gray, O. M. T. Davies, K. White, A. G. Ortega‐Loayza

    The introduction of biologics has rapidly expanded treatment options for patients suffering from severe plaque psoriasis. Currently, the mainstay of biologic therapy for psoriasis centers around three key classes: Anti‐tumor necrosis factor (TNF), Anti‐Interleukin (IL)‐23, and Anti‐IL‐17, such as Secukinumab and Ixekizumab. Though generally considered to have favorable safety profiles, there have been growing reports of dermatologic adverse events in the setting of biologic therapy initiation.


  • Open Access

    Case Report: Chilblains-like lesions (COVID-19 toes) during the pandemic - is there a diagnostic window?

    by Joanna Ludzik, Alexander Witkowski, Donna E. Hansel, Philipp W. Raess, Kevin White, Sancy Leachman

    The COVID-19 outbreak caused by the novel coronavirus, SARS-CoV-2, typically presents with symptoms including fever, cough, headache, myalgia, asthenia, anosmia, diarrhea, and sometimes pneumonia, which can be fatal. Recently, new dermatologic findings have been described in association with the disease that can potentially be a distinguishing feature of infection. One such feature resembles chilblains and this case report represents a presentation of this feature with a 48-year-old female with violaceous lesions with surrounding pink erythema on her toes who tested negative for COVID-19.


  • Open Access

    Case Report: Cutaneous chilblains-like lesions (CCLL) versus COVID-19 toes during the pandemic. Confocal findings and proposal for new acronym, CCLL – is there a diagnostic window?

    by Joanna Ludzik, Alexander Witkowski, Donna E. Hansel, Philipp W. Raess, Kevin White, Sancy Leachman

    The COVID-19 outbreak caused by the novel coronavirus, SARS-CoV-2, typically presents with symptoms including fever, cough, headache, myalgia, asthenia, anosmia, diarrhea, and sometimes pneumonia, which can be fatal. Recently, new dermatologic findings have been described in association with the disease that can potentially be a distinguishing feature of infection. One such feature resembles chilblains and this case report represents a unique presentation of this feature.

  • Open Access

    Ulcerative C2 neurocutaneous dysesthesia (trigeminal trophic syndrome in an alternative distribution)

    by Dylan Haynes, Christina Topham, Tamar Hajar, Alex G Ortega-Loayza, Kevin P White, Jesse J Keller

    Trigeminal trophic syndrome is an uncommon condition characterized by paresthesia, itch, and self-inflicted wounds following the trigeminal dermatome(s). Similar processes adhering to cervical nerve distributions have been reported, calling into question the specificity of trigeminal trophic syndrome for the trigeminal network. Herein, we report patient with trigeminal trophic syndrome adhering to the C2 dermatome, a previously unreported distribution.


  • Open Access

    Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies

    by Ludmila Perelygina, Min-Hsin Chen, Suganthi Suppiah, Adebola Adebayo, Emily Abernathy, Morna Dorsey, Lionel Bercovitch, Kenneth Paris, Kevin P White, Alfons Krol, et al.

    Rubella viruses (RV) have been found in an association with granulomas in children with primary immune deficiencies (PID). Here, we report the recovery and characterization of infectious immunodeficiency-related vaccine-derived rubella viruses (iVDRV) from diagnostic skin biopsies of four patients. Sequence evolution within PID hosts was studied by comparison of the complete genomic sequences of the iVDRVs with the genome of the vaccine virus RA27/3. The degree of divergence of each iVDRV correlated with the duration of persistence indicating continuous intrahost evolution. The evolution rates for synonymous and nonsynonymous substitutions were estimated to be 5.7 x 10−3 subs/site/year and 8.9 x 10−4 subs/site/year, respectively. Mutational spectra and signatures indicated a major role for APOBEC cytidine deaminases and a secondary role for ADAR adenosine deaminases in generating diversity of iVDRVs. The distributions of mutations across the genes and 3D hotspots for amino acid substitutions in the E1 glycoprotein identified regions that may be under positive selective pressure. Quasispecies diversity was higher in granulomas than in recovered infectious iVDRVs. Growth properties of iVDRVs were assessed in WI-38 fibroblast cultures. None of the iVDRV isolates showed complete reversion to wild type phenotype but the replicative and persistence characteristics of iVDRVs were different from those of the RA27/3 vaccine strain, making predictions of iVDRV transmissibility and teratogenicity difficult. However, detection of iVDRV RNA in nasopharyngeal specimen and poor neutralization of some iVDRV strains by sera from vaccinated persons suggests possible public health risks associated with iVDRV carriers. Detection of IgM antibody to RV in sera of two out of three patients may be a marker of virus persistence, potentially useful for identifying patients with iVDRV before development of lesions. Studies of the evolutionary dynamics of iVDRV during persistence will contribute to development of infection control strategies and antiviral therapies. Primary immunodeficiency diseases (PID) are caused by genetic defects and lead to serious problems including chronic granulomas (abnormal collections (nodules) of inflammatory cells), sometimes lasting for decades and sometimes leading to severe ulcers. Initial reports (2014–2016), including our report of a blinded study using ultrasensitive virus detection in biopsies, proved the association between granuloma of the skin in PID patients and rubella virus. The viruses in these reports and the current report were derived from a widely used vaccine strain of the rubella virus. Work reported here shows that these vaccine-derived viruses are biologically different from the vaccine virus and that their genomes have changed. Genomic changes could be analyzed largely because the exact sequence of starting vaccine virus genome was known. These genomic differences are likely generated via mechanisms similar to those occurring during normal circulation of wild type rubella. We present data that newly recognized mechanisms for generation of sequence diversity in viruses (because of cellular deaminases) likely occurs in the generation of these vaccine-derived rubella viruses. Thousands of PID patients in the United States are likely shedding these vaccine-derived rubella viruses. Our work presented here characterizing viruses in diagnostic specimens highlights at least two areas where insufficient work has been done: 1) research on the properties of rubella virus (limited understanding of the antibody binding sites on the virus); 2) controlled research studies to assess the public health impact of viruses in populations with high immunity.


  • Open Access

    Cutaneous Granulomatous Disease With Presence of Rubella Virus in Lesions

    by Julie Dhossche, Luke Johnson, Kevin White, Tracy Funk, Sabra Leitenberger, Ludmila Perelygina, Alfons Krol

    This case report describes 2 children with cutaneous granulomatous eruptions and rubella virus present in the lesions.